NuCana (NCNA) shares soared 164% amid heavy trading after the company said Saturday that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.
More than 50.1 million shares traded intraday compared with a daily average of about 138,000.
Nuvalent (NUVL) said Saturday that data from the ongoing parallel phase 1/2 trials of zidesamtinib and NVL-655 to treat non-small cell lung cancer showed "favorable tolerability."
Shares climbed 23%, with intraday trading volume at over 1.9 million compared with a daily average of about 344,000.
Zentalis Pharmaceuticals (ZNTL) said the US Food and Drug Administration lifted a partial clinical hold on studies of azenosertib, the company's novel and orally bioavailable inhibitor for advanced solid tumors.
Shares advanced 20% as intraday trading volume rose to 41.4 million versus the stock's daily average of about 1.49 million.
Price: 6.71, Change: +4.17, Percent Change: +164.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.